These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1006 related articles for article (PubMed ID: 25418708)
81. Perspectives on low-density lipoprotein cholesterol goal achievement. Catapano AL Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988 [TBL] [Abstract][Full Text] [Related]
82. 2017 Taiwan lipid guidelines for high risk patients. Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI; J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176 [TBL] [Abstract][Full Text] [Related]
83. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Morrone D; Weintraub WS; Toth PP; Hanson ME; Lowe RS; Lin J; Shah AK; Tershakovec AM Atherosclerosis; 2012 Aug; 223(2):251-61. PubMed ID: 22410123 [TBL] [Abstract][Full Text] [Related]
84. LIpid Response to Statins ± Ezetimibe In Mumbai (LIRIM): A Cross-sectional Observational Study. Shah VT J Assoc Physicians India; 2024 Sep; 72(9):64-72. PubMed ID: 39291519 [TBL] [Abstract][Full Text] [Related]
85. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. Lee S; Cannon CP Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475 [TBL] [Abstract][Full Text] [Related]
86. Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction ("Jena auf Ziel"). Makhmudova U; Samadifar B; Maloku A; Haxhikadrija P; Geiling JA; Römer R; Lauer B; Möbius-Winkler S; Otto S; Schulze PC; Weingärtner O Clin Res Cardiol; 2023 Sep; 112(9):1212-1219. PubMed ID: 36602598 [TBL] [Abstract][Full Text] [Related]
87. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E; J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343 [TBL] [Abstract][Full Text] [Related]
88. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Wójcik C Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791 [TBL] [Abstract][Full Text] [Related]
89. The 2013 ACC/AHA cardiovascular prevention guidelines improve alignment of statin therapy with coronary atherosclerosis as detected by coronary computed tomography angiography. Pursnani A; Mayrhofer T; Ferencik M; Hoffmann U Atherosclerosis; 2014 Nov; 237(1):314-8. PubMed ID: 25299966 [TBL] [Abstract][Full Text] [Related]
90. CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL-Cholesterol to ACC/AHA and ESC/EAS Targets. Mortensen MB; Steffensen FH; Bøtker HE; Jensen JM; Rønnow Sand NP; Kragholm KH; Kanstrup H; Sørensen HT; Leipsic J; Blaha MJ; Nørgaard BL JACC Cardiovasc Imaging; 2020 Sep; 13(9):1961-1972. PubMed ID: 32563656 [TBL] [Abstract][Full Text] [Related]
91. [New guidelines on dyslipidemia management: Comparison of French (HAS) and European (ESC/EAS) guidelines]. Farnier M Presse Med; 2018 Sep; 47(9):769-774. PubMed ID: 30274915 [TBL] [Abstract][Full Text] [Related]
92. DemographIc Assessment and EValuation of DEgree of Lipid Control in High Risk Indian DySlipidemia PatiEnts (DIVERSE Study). Malhotra N; Keshan MK; Agarwal A; Kumar RA; Trailokya A; Dalvi K; Talele S J Assoc Physicians India; 2016 Apr; 64(4):38-46. PubMed ID: 27734640 [TBL] [Abstract][Full Text] [Related]
93. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry. Brandts J; Tittel SR; Bramlage P; Danne T; Brix JM; Zimny S; Heyer CHJ; Holl RW; Müller-Wieland D Diabetes Obes Metab; 2023 Dec; 25(12):3700-3708. PubMed ID: 37694759 [TBL] [Abstract][Full Text] [Related]
94. Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors. Pinsdorf D; Messiha D; Petrikhovich O; Bahar M; Steinmetz M; Mahabadi AA; Dykun I; Lortz J; Rassaf T; Rammos C J Clin Lipidol; 2023; 17(4):504-511. PubMed ID: 37271601 [TBL] [Abstract][Full Text] [Related]
95. Implications of the 2013 ACC/AHA cholesterol guidelines on contemporary clinical practice for patients with atherosclerotic coronary and peripheral arterial disease. Gunasekaran P; Jeevanantham V; Sharma S; Thapa R; Gupta K Indian Heart J; 2017; 69(4):464-468. PubMed ID: 28822512 [TBL] [Abstract][Full Text] [Related]
97. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Rivers SM; Kane MP; Busch RS; Bakst G; Hamilton RA Endocr Pract; 2007; 13(1):11-6. PubMed ID: 17360295 [TBL] [Abstract][Full Text] [Related]
98. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R; JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642 [TBL] [Abstract][Full Text] [Related]
99. Can LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT II. Eber B; Lautsch D; Fauer C; Drexel H; Pfeiffer KP; Traindl O; Pichler M Curr Med Res Opin; 2012 Sep; 28(9):1447-54. PubMed ID: 22856551 [TBL] [Abstract][Full Text] [Related]
100. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Daskalopoulou SS; Mikhailidis DP Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]